| answer text |
<p>In 2015, the Independent Cancer Taskforce Report highlighted limited access to
molecular diagnostics across the National Health Service and limited use of technology
to systematically identify patients with cancer and suggested that this has resulted
in the NHS falling behind other countries in the delivery of high-quality, cost-effective
cancer care.</p><p>To address this, building on the world leading 100,000 Genomes
Project and the existing infrastructure, NHS England announced in October 2018 that
over the next 18 months work to mobilise the NHS Genomic Medicine Service (GMS) would
get underway. The GMS will bring together existing clinical genetics services and
the new genomic laboratory infrastructure to provide seamless service delivery for
patients with rare and inherited disease and cancer.</p>
|
 |
